ArriVent BioPharma, Inc. (AVBP) Balance Sheet
As of 2026-06-30 (10-Q), ArriVent BioPharma, Inc. (AVBP) reported total assets of $394.7M, total liabilities of $27.9M and shareholders' equity of $366.8M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $154.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVBPArriVent BioPharma, Inc.Follow AVBP — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|
| Cash and equivalents | 74.3 | 45.5 | 154.7 | |
| Short-term investments | 144.6 | 267.3 | 218.4 | |
| Current assets | 227.0 | 332.9 | 394.2 | |
| Total assets | 274.9 | 333.2 | 394.7 | |
| Current liabilities | 17.3 | 25.9 | 27.8 | |
| Total liabilities | 17.3 | 25.9 | 27.9 | |
| Shareholders' equity | 257.7 | 307.2 | 366.8 |
USD millions · SEC XBRL
ArriVent BioPharma, Inc. — questions
- How much cash does ArriVent BioPharma, Inc. have?
- $154.7M in cash and cash equivalents as of 2026-06-30.
- What are ArriVent BioPharma, Inc.'s total assets?
- $394.7M as of 2026-06-30.
- What is ArriVent BioPharma, Inc.'s shareholders' equity?
- $366.8M as of 2026-06-30.
Every figure on this page comes from ArriVent BioPharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.